Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis - Wikidata - wikimedia - TriplyDB

Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis

Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis

http://www.wikidata.org/entity/Q24185774

about

2.4 g Mesalamine (Asacol 400 mg tablet) Once Daily is as Effective as Three Times Daily in Maintenance of Remission in Ulcerative Colitis: A Randomized, Noninferiority, Multi-center Trial Induction of Colonic Regulatory T Cells by Mesalamine by Activating the Aryl Hydrocarbon Receptor Management of ulcerative colitis in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease.Real life results in using 5-ASA for maintaining mild to moderate UC patients in Japan, a multi-center study, OPTIMUM Study.Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's disease.5-Aminosalicylates to maintain remission in Crohn's disease: Interpreting conflicting systematic review evidence.Positioning of old and new biologicals and small molecules in the treatment of inflammatory bowel diseases

P2860

Q33601419-1DAB13F1-05BE-4427-83A1-1EA5FBBC9CFF Q33752706-FE25AD2B-E2F6-4BC4-BCDB-8AC31641434A Q33819473-0708BF7E-DEDA-4A1C-9757-50F1FE29B049 Q36340943-F62DA529-7897-4353-BA8E-D4CC731739E9 Q38967059-10C604EB-E6C7-4099-A308-F6C3E685E02F Q42353913-1B32B92C-C8F5-4B78-9081-1DB3882537A2 Q57167308-4FA1B916-D224-4611-A0D4-683ADB4A49C1

P2860

Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis

http://www.wikidata.org/entity/Q24185774

description

2016 nî lūn-bûn

@nan

2016 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis

@ast

Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis

@en

Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis

@en-gb

Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis

@nl

type

label

Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis

@ast

Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis

@en

Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis

@en-gb

Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis

@nl

prefLabel

Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis

@ast

Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis

@en

Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis

@en-gb

Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis

@nl

P1433

Q24185774-E0AFC24F-BA0F-49F0-AD24-C633539FFCD4

P1476

Q24185774-75F6AF54-AA1B-4A8C-890B-3DC183541D36

P2093

Q24185774-0E9CF337-B4F9-4CF6-B85F-FC18077A7223

Q24185774-17F35371-95C6-42D9-BC4E-71917CABB97D

Q24185774-26FA9B7B-662B-4C72-90DF-8F069FD8E2F9

Q24185774-9EA2CE7F-C020-492C-8D0A-701CB0B8B4C6

P2860

Q24185774-0485A63E-AF19-40D7-9A41-89FD3A30E3B2

Q24185774-074F3994-A57E-4F3E-A3D5-2B52352588D1

Q24185774-0997DBAC-A6EE-4FB6-90F5-7E158CA197DD

Q24185774-0AE233D4-D973-4A0C-94E0-67FD1C646A8A

Q24185774-21189BBE-57A0-45D6-A413-36AA06DCFDEE

Q24185774-2A26D9A8-EBAE-4CF0-9470-F3552FF584E7

Q24185774-2F7B4973-7C6A-458F-AA46-582021953E8B

Q24185774-4E5282E7-B0E6-4913-8862-AD473BDF1D18

Q24185774-513DA9E9-323A-474F-9D71-827C3115FE75

Q24185774-52E5B85A-3900-42F7-A6CB-0920B7DD5FB7

P304

Q24185774-BB4C4B8A-698E-4C6A-9F3F-36545E4FA1FB

P31

Q24185774-7873d180-8ef4-4eb9-9cd7-5f66af0aba06

Q24185774-E482A7BD-88C9-4457-85FE-E8793F9E5793

Q24185774-dafcab5c-7d8f-4a5c-87bd-848a5e9ca5f4

P356

Q24185774-CF64F474-B451-4490-9849-23FC8BB80276

P433

Q24185774-FE747182-E10D-454A-879A-E282AE963B89

P50

Q24185774-03F69BD3-1DF0-48E0-A44B-59469AF388A0

P577

Q24185774-2C9180C3-ACC8-40AD-8045-55A5F00EAB15

P698

Q24185774-42B4B9CF-BB0E-4F3A-A9C9-A9F5E275EC84

P932

Q24185774-3E2BC870-87AE-42B2-BE0E-ECF71721A0BF

P356

14651858.CD000544.PUB4

P1433

Cochrane Database of Systematic Reviews

P1476

Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis

@en

P2093

Brian G Feagan

http://www.w3.org/2001/XMLSchema#string

Claire E Parker

http://www.w3.org/2001/XMLSchema#string

John K MacDonald

http://www.w3.org/2001/XMLSchema#string

Yongjun Wang

http://www.w3.org/2001/XMLSchema#string

P2860

Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine

Measuring inconsistency in meta-analyses

GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

Randomized clinical trial of Plantago ovata seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis. Spanish Group for the Study of Crohn's Disease and Ulcerative Colitis (GETECCU)

Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses

Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype

Direct comparison of two different mesalamine formulations for the maintenance of remission in patients with ulcerative colitis: a double-blind, randomized study.

Optimum dose of olsalazine for maintaining remission in ulcerative colitis.

Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion

Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine

P304

CD000544

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/14651858.CD000544.PUB4

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P50

Brian G. Feagan

P577

2016-05-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27158764

http://www.w3.org/2001/XMLSchema#string

P932

7045447

http://www.w3.org/2001/XMLSchema#string